ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Reagentless Real-Time ATP Monitoring with New DNA Aptamers.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A high-affinity dopamine aptamer: implications of library diversity and negative selection.Chemical science · 2026Article
- Capture-SELEX of DNA Aptamers for Highly Selective Binding of Folate.Chembiochem : a European journal of chemical biology · 2026Article
- Reagentless Real-Time ATP Monitoring with New DNA Aptamers.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Adenosine triphosphate (ATP) is essential to numerous biological processes, and there is considerable interest in methods for measuring this molecule in real time. Current ATP sensors have fundamental shortcomings that limit their utility, such as poor specificity, the need for exogenous reagents, or assay complexity. Aptamer-based biosensors have shown great promise for ATP detection, but existing aptamers have modest affinity and poor specificity that limit their practical utility. Here, the systematic evolution of ligands by exponential enrichment (SELEX) process is used to discover new DNA aptamers that bind ATP with unprecedentedly high affinity and specificity. The best-performance aptamer, ATP18-13, displays at least tenfold greater affinity for ATP relative to previously reported aptamers, with far superior capacity to discriminate against analogs including adenosine diphosphate (ADP), adenosine monophosphate (AMP), and adenosine. ATP18-13 is used to develop a fluorescent beacon sensor that achieves a limit of detection of 125 nm ATP in buffer and 1 µm ATP in cell culture medium. The capability of this sensor is demonstrated to achieve real-time, seconds-scale monitoring of deoxyATP consumption during DNA polymerase-mediated template extension. The aptamers and sensors developed here can thus prove useful for monitoring ATP in a variety of biological contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.